Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 12/20 | 0.49 |
| ▸ | JAK1 | P23458 | 8/20 | 0.49 |
| ▸ | JAK3 | P52333 | 4/20 | 0.44 |
| ▸ | PAK1 | Q13153 | 6/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CDK7 | P50613 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | CCNH | P51946 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14634149 | 0.89 | CCNT1 (0.43) | JAK2JAK1JAK3CCNT1CDK1 | |
| SCHEMBL14634077 | 0.86 | JAK1 (0.40) | JAK2JAK1JAK3CCNT1CDK1 | |
| SCHEMBL14634260 | 0.85 | JAK2 (0.45) | JAK2JAK1JAK3PAK1CCNT1 | |
| SCHEMBL14633989 | 0.84 | SYK (0.42) | JAK2JAK1JAK3CCNT1CDK2 | |
| SCHEMBL14634231 | 0.82 | CCNT1 (0.48) | JAK2JAK1JAK3CCNT1CDK1 | |
| SCHEMBL14634234 | 0.79 | JAK3 (0.42) | JAK2JAK1JAK3BRD4CCNT1 | |
| SCHEMBL14634005 | 0.77 | LRRK2 (0.42) | CCNT1CDK2CDK9 | |
| SCHEMBL14634185 | 0.77 | EPHB4 (0.49) | JAK2JAK1JAK3PAK1 | |
| SCHEMBL2463301 | 0.77 | JAK2 (0.42) | JAK2JAK1JAK3PAK1 | |
| SCHEMBL14633643 | 0.77 | CDK2 (0.39) | JAK2JAK1JAK3CCNT1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | claimed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | claimed |
| EP-2552211-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | Glaxo Group Limited (GB) | 2013-02-06 | — | — | EP | disclosed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| WO-2011120025-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | MAP3K19, MAP3K1, MAP3K20 | JAK2 45/4885JAK1 58/4885JAK3 102/4885 |
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | CDK2, MAP3K19, MAP3K1 | JAK2 98/4885JAK1 93/4885JAK3 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.